Factors associated with late recurrence after completion of 5-year adjuvant tamoxifen in estrogen receptor positive breast cancer

BACKGROUND: Recent large trials have shown the survival benefits of 10-year use of tamoxifen by reducing late recurrence compared with 5-year therapy in estrogen receptor(ER)-positive breast cancer. We tried to identify clinical factors associated with the late recurrence. METHODS: We reviewed our d...

Descripción completa

Detalles Bibliográficos
Autores principales: Lee, Eun-Shin, Han, Wonshik, Kim, Min Kyoon, Kim, Jongjin, Yoo, Tae-kyung, Lee, Moo Hyun, Lee, Kyung Hun, Kim, Tae Yong, Moon, Hyeong-Gon, Im, Seock-Ah, Noh, Dong-Young, Lee, Eun Sook
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4937609/
https://www.ncbi.nlm.nih.gov/pubmed/27388210
http://dx.doi.org/10.1186/s12885-016-2423-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4937609/
https://www.ncbi.nlm.nih.gov/pubmed/27388210
http://dx.doi.org/10.1186/s12885-016-2423-x

Ejemplares similares